Avacincaptad pegol is in clinical development for the treatment of adults with geographic atrophy secondary to dry age-related macular degeneration (dry AMD). AMD causes gradual, irreversible damage to the centre of the retina of the eye, called the macula, which is needed for seeing visual details. In advanced disease, patches of damage called geographical atrophy (GA) develop on the retina, causing blind spots. It is thought that GA is caused when ageing processes in the retina cause inflammation that starts to cycle out of control, destroying retina cells. GA is irreversible, and it cannot be prevented as ageing is the main risk factor. It is a leading cause of vision loss in the UK. Central vision loss caused by GA increases dependency, vulnerability to falls, and can lead to depression. Currently, there are no recommended treatments for GA in the UK.
Avacincaptad pegol for the treatment of geographic atrophy secondary to age-related macular degeneration
Avacincaptad pegol is in clinical development for the treatment of adults with geographic atrophy secondary to dry age-related macular degeneration (dry AMD). AMD causes gradual, irreversible damage to the centre of the retina of the eye, called the macula, which is needed for seeing visual details.